Acasti Surges on Year-End Figures

By: Dylan Sikes – AllPennyStocks.com News

Wednesday, June 26, 2019

The long-awaited fiscal year-end numbers released by Laval, Quebec-based Acasti Pharma Inc. (TSX-Venture:ACST) provided a springboard for its stock price on Wednesday.

The company, calling itself “a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre®(omega-3 phospholipid),” pointed to $34.4 million of cash, cash equivalents and marketable securities by year’s end.

Net loss for the year ended March 31, 2019 was $51.6 million or $0.95 per share, compared to a net loss of $21.5 million or $1.23 per share for the prior-year.

CEO Jan D’Alvise commented, “Fiscal 2019 was an eventful year for the Company as we achieved several key milestones related to our ongoing Phase 3 clinical trials, which remain on schedule and within budget. We recently announced that we had achieved 100% patient randomization in both TRILOGY clinical studies, and more than 60% of patients have now completed the trial.”

Share prices gained 16 cents, or 11.3%, by midday Wednesday to $1.58, on exciting volume of 476,000 shares.

Copyright © 2019 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon